Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2021

	As of December 31,
	2021		2020

Prepaid expenses and other current assets
Prepaid insurance	$	769,416	$	68,003
Prepaid research and development costs		-		7,050
Deferred offering costs		55,718		-
Total prepaid expenses and other current assets	$	825,134	$	75,053

Accrued and other current liabilities
Accrued interest payable	$	-	$	49,169
Accrued research and development costs		235,384		-
Accrued compensation and benefits		766,207		84,308
Total accrued and other current liabilities	$	1,001,591	$	133,477